Fig. 6: Delineation of the metastatic evolution of GISTs.

a Diagram of metastatic foci (P = primary GIST; M=metastatic GIST), time to recurrence (m=months, yr=years) and TKI target therapy (IM = imatinib, SU = sunitinib, Naïve = no TKI therapy). b Heatmaps indicate the cancer cell fraction (CCF) of non-silent mutations in each lesion from 4 patients. The number of mutations is labeled on the left. The percentage of truncal (purple) and private (yellow) mutations is labeled on the right. c Identified regions of CNV and copy-neutral (CN-LOH) in each lesion from 4 patients. The percentage of truncal CNVs is labeled at the center of the Circos plot. d Phylogenetic trees of 4 patients based on all non-silent mutations. Branch and trunk lengths are proportional to their number mutations. Selected cancer-associated genes and truncal CNV arms are indicated with arrows. For non-silent mutations: purple=mutations present in all samples; green=mutations shared by partial samples, yellow=private mutations. For CNVs: truncal arm-level copy number deletion events are labeled in blue, and truncal arm-level copy number amplification events are labeled in red. e Relative contribution of 6 base mutations in the trunks (left circles) and branches (right circles). Trunk equals to truncal SNVs in (b), branch equals to shared and private SNVs in (b). Source data are provided as a Source Data file.